Clinicopathological Characteristics and Prognosis of Metaplastic Breast Cancer Versus Triple-negative Invasive Ductal Carcinoma: a Retrospective Analysis

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2023 Nov 23

PMID 37996840

Authors

Xiaolu Yang

Tiantian Tang

Tao Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Metaplastic breast cancer(MBC) is a specific pathological type of invasive breast cancer. There are few studies related to MBC due to its rarity. This study aimed to analyse the differences in clinicopathological characteristics and prognosis between Metaplastic breast cancer and triple-negative invasive ductal carcinoma (TN-IDC).

Methods: We retrospectively compared the clinicopathological characteristics of patients diagnosed with MBC and TN-IDC at the Fourth Hospital of Hebei Medical University between 2011 and 2020 in a 1:2 ratio. The log-rank test was used to compare the two groups' disease-free survival (DFS) and overall survival (OS). For MBCs, we performed univariate and multivariate analyses using the Cox proportional hazards model to determine the characteristics that impacted OS and DFS.

Results: A total of 81 patients with MBC and 162 patients with TN-IDC were included in this study. At initial diagnosis, MBC patients had larger tumour diameters(P = 0.03) and fewer positive lymph nodes (P = 0.04). Patients with MBC were more likely to have organ metastases after surgery (P = 0.03). Despite receiving the same treatment, MBC patients had worse DFS (HR = 1.66, 95%CI 0.90-3.08, P = 0.11) and OS (HR = 1.98, 95% CI 1.03-3.81, P = 0.04), and OS was statistically significant. Positive lymph nodes at initial diagnosis were associated with worse DFS (HR = 3.98, 95%CI 1.05-15.12, P = 0.04) and OS (HR = 3.70, 95%CI 1.03-13.34, P = 0.04) for patients with MBC. The efficacy of platinum-based agents is insensitive for MBC patients receiving chemotherapy. In addition, patients treated with preoperative chemotherapy had worse DFS compared to patients treated with postoperative chemotherapy (HR = 3.51, 95%CI 1.05-11.75, P = 0.04).

Conclusions: The clinicopathological characteristics and prognosis of MBC and TN-IDC differ in many ways. Further studies are required to determine suitable treatment guidelines for patients with MBC.

Citing Articles

Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.

Zhang Y, An W, Wang C, Liu X, Zhang Q, Zhang Y Breast. 2024; 79:103858.

PMID: 39675092 PMC: 11699302. DOI: 10.1016/j.breast.2024.103858.

References

Beatty J, Atwood M, Tickman R, Reiner M . Metaplastic breast cancer: clinical significance. Am J Surg. 2006; 191(5):657-64. DOI: 10.1016/j.amjsurg.2006.01.038. View

Wright G, Davis A, Koehler T, Melnik M, Chung M . Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol. 2014; 21(11):3497-503. DOI: 10.1245/s10434-014-3782-7. View

Pezzi C, Patel-Parekh L, Cole K, Franko J, Klimberg V, Bland K . Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2006; 14(1):166-73. DOI: 10.1245/s10434-006-9124-7. View

He X, Ji J, Dong R, Liu H, Dai X, Wang C . Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Res Treat. 2018; 173(2):329-341. DOI: 10.1007/s10549-018-5005-6. View

Chen I, Lin C, Huang C, Lien H, Hsu C, Kuo W . Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011; 130(1):345-51. DOI: 10.1007/s10549-011-1686-9. View

Morgan E, Suresh A, Ganju A, Stover D, Wesolowski R, Sardesai S . Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. World J Surg Oncol. 2020; 18(1):11. PMC: 6961248. DOI: 10.1186/s12957-019-1780-8. View

Zhang J, Yang C, Lei C, Zhang Y, Ji F, Gao H . Survival outcomes after breast-conserving therapy compared with mastectomy for patients with early-stage metaplastic breast cancer: a population-based study of 2412 patients. Breast. 2021; 58:10-17. PMC: 8080072. DOI: 10.1016/j.breast.2021.03.010. View

Li Y, Zhang N, Zhang H, Yang Q . Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. J Clin Pathol. 2019; 72(6):418-424. DOI: 10.1136/jclinpath-2018-205544. View

Aydiner A, Sen F, Tambas M, Ciftci R, Eralp Y, Saip P . Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment. Medicine (Baltimore). 2015; 94(52):e2341. PMC: 5291613. DOI: 10.1097/MD.0000000000002341. View

10.

Yadav B, Chanana P, Jhamb S . Biomarkers in triple negative breast cancer: A review. World J Clin Oncol. 2015; 6(6):252-63. PMC: 4675910. DOI: 10.5306/wjco.v6.i6.252. View

11.

Lee H, Jung S, Ro J, Kwon Y, Sohn J, Park I . Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012; 65(5):441-6. DOI: 10.1136/jclinpath-2011-200586. View

12.

Huvos A, LUCAS Jr J, FOOTE Jr F . Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med. 1973; 73(9):1078-82. View

13.

Carter C, Allen C, Henson D . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-7. DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. View

14.

Jung S, Kim H, Nam B, Min S, Lee S, Park C . Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010; 120(3):627-37. DOI: 10.1007/s10549-010-0780-8. View

15.

McKinnon E, Xiao P . Metaplastic carcinoma of the breast. Arch Pathol Lab Med. 2015; 139(6):819-22. DOI: 10.5858/arpa.2013-0358-RS. View

16.

Xia L, Xu W, Hu Q . The different outcomes between breast-conserving surgery plus radiotherapy and mastectomy in metaplastic breast cancer: A population-based study. PLoS One. 2021; 16(9):e0256893. PMC: 8412345. DOI: 10.1371/journal.pone.0256893. View

17.

Bae S, Lee S, Koo M, Hur S, Choi M, Cho D . The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011; 126(2):471-8. DOI: 10.1007/s10549-011-1359-8. View

18.

Song Y, Liu X, Zhang G, Song H, Ren Y, He X . Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013; 11:129. PMC: 3679991. DOI: 10.1186/1477-7819-11-129. View

19.

Hennessy B, Giordano S, Broglio K, Duan Z, Trent J, Buchholz T . Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006; 17(4):605-13. DOI: 10.1093/annonc/mdl006. View

20.

Weigelt B, Ng C, Shen R, Popova T, Schizas M, Natrajan R . Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. . Mod Pathol. 2014; 28(3):340-51. PMC: 4523239. DOI: 10.1038/modpathol.2014.142. View